Photo from wikipedia
Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis (IPF). Although optimal treatment for AE‐IPF remains unclear, high‐dose corticosteroids (CS) with/without immunosuppressants, including intravenous… Click to show full abstract
Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis (IPF). Although optimal treatment for AE‐IPF remains unclear, high‐dose corticosteroids (CS) with/without immunosuppressants, including intravenous cyclophosphamide (IVCY), are often used as empirical therapy. However, the survival benefit of adding IVCY to CS therapy is unknown. We investigated the efficacy of this therapy in patients with AE‐IPF.
Keywords:
idiopathic pulmonary;
intravenous cyclophosphamide;
pulmonary fibrosis;
acute exacerbation
Journal Title: Respirology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Respirology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!